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The antitumour activity of a medicinal mushroom Phellinus linteus (PL), through the stimulation of immune system or the induction of
apoptosis, has been recently described. However, the molecular mechanisms responsible for the inhibition of invasive behaviour of
cancer cells remain to be addressed. In the present study, we demonstrate that PL inhibits proliferation (anchorage-dependent
growth) as well as colony formation (anchorage-independent growth) of highly invasive human breast cancer cells. The growth
inhibition of MDA-MB-231 cells is mediated by the cell cycle arrest at S phase through the upregulation of p27
Kip1 expression.
Phellinus linteus also suppressed invasive behaviour of MDA-MB-231 cells by the inhibition of cell adhesion, cell migration and cell
invasion through the suppression of secretion of urokinase-plasminogen activator from breast cancer cells. In addition, PL markedly
inhibited the early event in angiogenesis, capillary morphogenesis of the human aortic endothelial cells, through the downregulation of
secretion of vascular endothelial growth factor from MDA-MB-231 cells. These effects are mediated by the inhibition of serine-
threonine kinase AKT signalling, because PL suppressed phosphorylation of AKT at Thr
308 and Ser
473 in breast cancer cells. Taken
together, our study suggests potential therapeutic effect of PL against invasive breast cancer.
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Despite the fact that breast cancer mortality of breast cancer
decreased by 22.9% from 1991 to 2003, breast cancer remains the
leading cause of cancer death among 20- to 59-year-old US women
with estimated 40460 new death in 2007 (Jemal et al, 2007). One of
the reasons for such a high mortality is the invasive behaviour of
cancer cells, which results in the metastasis of breast cancer.
Cancer metastasis consists of several interdependent processes
including uncontrolled cell proliferation, invasion through sur-
rounding tissues, migration to the distant sites of the human body,
and adhesion, invasion and colonisation of other organs and
tissues (Price et al, 1997). Tumour growth and metastasis also
require angiogenesis, the formation of blood vessels by capillaries
sprouting from pre-existing vessels (Folkman, 1995). Therefore,
inhibition of growth, invasive behaviour and cancer cell-mediated
angiogenesis will lead to the suppression of cancer metastasis and
would further increase survival of breast cancer patients.
Phellinus linteus (PL) is a basidiomycete fungus, located mainly
in tropical America, Africa and Asia, where it gained significant
recognition as medicinal mushroom in the traditional Oriental
medicine (Dai and Xu, 1998). The biologically active compounds
isolated from PL are polysaccharides (Song et al, 1995), acidic
proteo-heteroglycans with mixed a- and b-linkages, and a (1-6)-
branched type (1-3)-glycan (Kim et al, 2003b). These complex
polysaccharides have been detected in a variety of different
mushroom species and linked to the immunostimulatory and
antitumour activities (Wasser, 2002). Therefore, PL stimulated
proliferation of T lymphocytes and activated B cells (Kim et al,
1996, 2003c), and induced maturation of bone marrow-derived
dendritic cells (Park et al, 2003) and the macrophage response
(Kim et al, 2003a). On the other hand, PL demonstrated anti-
inflammatory effects in lipopolysaccharide-stimulated macro-
phages (Kim et al, 2006). The direct anticancer effect of PL has
been demonstrated by the inhibition of invasive melanoma B16BL6
cells through the downregulation of mRNA level of urokinase-
plasminogen activator (uPA), and by the inhibition of pulmonary
metastasis in mice (Lee et al, 2005). Phellinus linteus suppressed
proliferation by the inhibition of cyclin-dependent kinases cdk2, 4
and 6, and induced apoptosis through the activation of caspase 3 in
lung cancer cells (Guo et al, 2007) and apoptosis of prostate cancer
cells (Collins et al, 2006; Zhu et al, 2007).
In the present study, we evaluated the effect of PL on the highly
invasive and metastatic human breast cancer cells. Here, we show
that PL inhibits proliferation (anchorage-dependent growth) as
well as colony formation (anchorage-independent growth) of
highly invasive human breast cancer cells. In addition, PL also
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inhibition of cell adhesion, cell migration and cell invasion.
Finally, PL suppressed breast cancer cell-mediated angiogenesis of
endothelial cells in vitro. Collectively, our study suggests the
mechanism(s) employed for the inhibition of proliferation,
invasive behaviour and angiogenesis of invasive breast cancer
cells by an extract from medicinal mushroom PL.
MATERIALS AND METHODS
Cell culture and reagents
Human breast cancer cells (MCF-7, MDA-MB-231) and human
prostate cancer cells (PC-3, LNCaP) were obtained from ATCC
(Manassas, VA, USA). MCF-7 and MDA-MB-231 cells were
maintained in DMEM medium, PC-3 cells were maintained in F-
12 medium and LNCaP cells were maintained in RPMI 1640
medium. All media contained penicillin (50Uml
 1), streptomycin
(50Uml
 1), and 10% fetal bovine serum (FBS). Media and
supplements came from GIBCO BRL (Grand Island, NY, USA).
Fetal bovine serum was obtained from Hyclone (Logan, UT, USA).
Aqueus extract of PL was supplied by the Maitake Products Inc.
(Paramus, NJ, USA). Stock solution was prepared by dissolving PL
in sterile water at a concentration 50mgml
 1 and stored at 41C.
AKT inhibitors LY294002 and AKT inhibitor III were obtained
from Calbiochem (San Diego, CA, USA).
Cell proliferation assay
Cell proliferation was determined by the tetrazolium salt method,
according to the manufacturer’s instructions (Promega, Madison,
WI, USA). Briefly, cancer cells were cultured in a 96-well plate and
treated at indicated times with PL (0–1.0mgml
 1). At the end of
the incubation period, the cells were harvested and absorption was
determined with an ELISA plate reader at 570nm, as described
(Jiang et al, 2004b). Data points represent mean±s.d. in the
representative experiment of triplicate determinations. Similar
results were obtained in two independent experiments.
Cell viability
Cell viability of MCF-7 and MDA-MB-231 cells was determined
after incubation with PL (0–1.0mgml
 1) for 24, 48 and 72h by
staining with Trypan Blue as described (Sliva et al, 2002a).
Anchorage-independent growth
MDA-MB-231 cells were harvested and seeded in six-well plates
coated with 1% agarose. Anchorage-independent growth was
assessed after incubation for 10–14 days with culture media with
or without PL (0–1.0mgml
 1), which were replaced every 4 days.
Plates were stained with 0.005% crystal violet, and the colonies
were counted manually under a microscope and photographed
(Slivova et al, 2004).
Cell cycle analysis
MDA-MB-231 cells (0.75 10
6) were seeded and after 24h treated
with PL (0.5mgml
 1) for the indicated period of time (0–48h).
After incubation, the cells were harvested by trypsinisation,
washed with Dulbecco’s phosphate-buffered saline containing 2%
FBS, and resuspended in propidium iodine (50mgml
 1). Cell cycle
analysis was performed on a FACStar
PLUS flow cytometer (Becton-
Dickinson, San Jose, CA, USA), as previously described (Sliva et al,
2001). Data are the mean±s.d. from three independent
experiments.
Cell adhesion, migration and invasion assays
Cell adhesion was performed with Cytomatrix Adhesion Strips
coated with human vitronectin (Chemicon International, Teme-
cula, CA, USA). Briefly, MDA-MB-231 cells were treated with PL
(0–0.5mgml
 1) for 24h, harvested and counted. Cell adhesion
was determined after 1.5h of incubation at 371C (Lloyd et al,
2003). Cell migration of MDA-MB-231 cells treated with PL
(0–1.0mgml
 1) was assessed in Transwell chambers in the DMEM
medium containing 10% FBS (Slivova et al, 2004). Invasion of
MDA-MB-231 cells treated with PL (0–1.0mgml
 1) was assessed
in Transwell chambers coated with 100ml of Matrigelt (BD
Biosciences, Bedford, MA, USA) diluted 1:4 with DMEM, after 72h
of incubation (Slivova et al, 2004).
In vitro endothelial cell morphogenesis assay (capillary
morphogenesis)
Human aortic endothelial cell (HAEC) differentiation into
‘capillary-like’ structures was observed using a two-dimensional
Matrigel-based assay as we described previously (Harvey et al,
2002). Initially, 200ml of ice-cold growth factor-reduced Matrigel
(Becton Dickinson Labware, Bedford, MA, USA), an extracellular
matrix preparation derived from the Engelbreth–Holm–Swarm
tumour, was placed into each well of a 24-well tissue culture-
treated plate. Human aortic endothelial cells were harvested,
resuspended in serum-free EBM media and plated at 3.5 10
4 cells
per well-coated with Matrigel. Human aortic endothelial cells were
further incubated with PL (0–0.5mgml
 1) or with conditioned
media from MDA-MB-231 cells, which were prepared by the
incubation of MDA-MB-231 cells in the presence of PL
(0–0.5mgml
 1) for 24h. Endothelial HAE cells differentiated into
capillary-like structures within 16h of incubation at 371C in the
presence of 5% CO2. These structures were examined micro-
scopically ( 40) using an inverted Olympus CK40 microscope. To
facilitate analysis of the structures, non-adherent cells incorpo-
rated in excess medium were removed from each well prior to
quantitative analysis. Photomicrographs were taken to assess the
extent of capillary-like structural formation. Quantification of the
capillary-like structures was performed counting the number of
nodes per field, where a node is defined as an intersection of at
least three cells. Each sample was assayed in triplicate and
reproduced in at least two additional experiments.
Western blot analysis
MDA-MB-231 cells were treated with PL (0–1.0mgml
 1) for
24–72h as indicated in the text and whole-cell extracts prepared as
described previously (Sliva et al, 2002a,b). Equal amounts of
proteins (20mg per lane) were separated on NuPAGE 4–12% Bis-
Tris gel (Invitrogen, Carlsbad, CA, USA) and transferred to a
PVDF membrane (Millipore, Bedford, MA, USA). The protein
expression was detected with the corresponding primary anti-
bodies: anti-cyclin-D1, anti-cyclin-E, anti-cyclin-A, anti-cdk2, anti-
cdk4, anti-p21, anti-p27, anti-b-actin, (Santa, Cruz Biotechnology,
Santa Cruz, CA, USA), anti-AKT, anti-phospho-AKT (Thr
308) and
anti-phospho-AKT (Ser
473) (Cell Signaling, Beverly, MA, USA),
respectively. Protein expression was visualised using the ECL
Western Blotting Detection System (Amersham Biosciences,
Buckinghamshire, UK).
Urokinase-plasminogen activator secretion
DMEM media from MDA-MB-231 cells treated with PL
(0–1.0mgml
 1) for 24h were collected and concentrated, and
the secretion of uPA was detected by western blot analysis with
anti-uPA antibody (Oncogene Research Products, Cambridge, MA,
USA), as described (Sliva et al, 2002b).
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Autoradiograms of the western blots were scanned with HP scanjet
5470c scanner. The optical densities of p27, phospho-AKT
(Thr
308), phospho-AKT (Ser
473), AKT, b-actin and uPA proteins
on the films were quantified and analysed with the UN-SCAN-IT
software (Silk Scientific, Orem, UT, USA). The ratios of p27/b-
actin and phosphoAkt/Akt were calculated by standardising the
ratios of each control to the unit value.
Vascular endothelial growth factor secretion
MDA-MB-231 cells were treated with PL (0–0.5mgml
 1) for 24h,
cell media collected and secretion of vascular endothelial growth
factor (VEGF) was determined using a respective Quantikine
ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions.
Statistical analysis
Data are presented as means±s.d. Statistical comparison between
the control group (0mgml
 1 of PL) and groups with different PL
doses was carried out using two-sided Student’s t-tests. The value
of Po0.05 was considered to be significant.
RESULTS
Phellinus linteus suppresses proliferation and colony
formation of highly invasive breast cancer cells
Invasive behaviour of cancer cells is directly linked to their
metastatic potential resulting in the high cancer mortality.
Therefore, we evaluated if PL inhibits growth of highly invasive
(MDA-MB-231) and poorly invasive (MCF-7) breast cancer cells.
As seen in Figure 1, increased concentration of PL (0–1.0mgml
 1)
markedly suppressed proliferation of MDA-MB-231 as well as
MCF-7 cells in a dose- and time-dependent manner. Nevertheless,
the effect of PL on poorly invasive cells was more pronounced,
because the concentration 0.25, 0.5 and 1.0mgml
 1 of PL
suppressed proliferation of MCF-7 cells by 60.2, 70.1 and 78.0%,
respectively (Figure 1B), whereas the same concentration sup-
pressed proliferation of MDA-MB-231 cells by 15.5, 21.5 and
43.1%, respectively (Figure 1A), after 24h of incubation. The same
sensitivity of MCF-7 cells was evident also after additional 48 and
72h of incubation, where only the highest concentration of PL
(1.0mgml
 1) suppressed proliferation of poorly invasive and
highly invasive breast cancer cells with the same potency (Figure 1).
To determine if the effect of PL on cancer cells is cytotoxic or
cytostatic, we evaluated the cell viability after 24, 48 and 72h of PL
treatment. Although PL decreased the viability of MDA-MB-231
and MCF-7 cells, the strongest inhibition of cell viability at the
highest used concentration of PL (1.0mgml
 1) after 72h was only
13.5% for MDA-MB-231 cells (Figure 1C) and 10.6% for MCF-7
cells (Figure 1D), whereas the same concentration suppressed
proliferation of MDA-MB-231 cells by 86.6% (Figure 1A) and
MCF-7 cells by 90.6% (Figure 1B). Therefore, these data suggest
that the PL inhibits growth of breast cancer cells predominantly
through its cytostatic effect. Interestingly, PL also suppressed
proliferation of poorly invasive prostate (LNCaP) and highly
invasive prostate (PC-3) cancer cells in a dose- and time-
dependent manner, and LNCaP cells were more sensitive to the
PL treatment (not shown).
In addition to cell proliferation (anchorage-dependent growth),
colony formation (anchorage-independent growth) is one of the
typical characteristic of the metastatic potential of cancer cells
in vitro and strongly correlates with tumorigenesis in vivo
(Freedman and Shin, 1974). To determine whether PL suppresses
colony formation of highly invasive breast cancer cells, we
evaluated the anchorage-independent growth of MDA-MB-231
cells. As seen in Figure 2, MDA-MB-231 cells formed colonies on
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Figure 1 Effect of PL on proliferation of breast cancer cells. Proliferation: (A) MDA-MB-231, (B) MCF-7 cells were treated with PL (0–1.0mgml
 1) for
24, 48 and 72h. Cell proliferation was determined as described in Materials and Methods. Data are the means±s.d. of triplicate determinations. Similar
results were obtained in at least two additional experiments. *Po0.05. Viability: (C) MDA-MB-231, (D) MCF-7 cells were treated with PL (0–1.0mgml
 1)
for 24, 48 and 72h. Cell viability was determined by Trypan blue staining as described in Materials and Methods. Data are the means±s.d. of triplicate
determinations. Similar results were obtained in at least one additional experiment. *Po0.05.
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concentration of PL (0–1.0mgml
 1) resulted in the significant
suppression of number of colonies (Figure 2E). Therefore, PL
inhibits anchorage-dependent as well as anchorage-independent
growth of highly aggressive breast cancer cells.
Phellinus linteus induces cell cycle arrest at S phase
To determine whether the inhibition of cell proliferation is
associated with cell cycle arrest, MDA-MB-231 cells were treated
for 24 and 48h with PL (0.5mgml
 1) and analysed by flow
cytometry. Cell cycle analysis demonstrated that PL causes cell
cycle arrest at S phase of cell cycle (Table 1), where the amount of
cells in S phase significantly increased from 27% (control – 0h) to
34% (24h) and 44% (48h). In addition, PL treatment did not
induce the amount of cells in sub-G0/G1 phase, further suggesting
the cytostatic effect of PL on MDA-MB-231 cells (Table 1). To
examine the mechanism responsible for the cell cycle arrest at S
phase, we evaluated the expression of cell cycle regulatory proteins
(cyclins) and cdks involved in the progression from G1 phase to S
phase (Sherr and Roberts, 1999; Ekholm and Reed, 2000).
Therefore, MDA-MB-231 cells were treated with PL
(0–1.0mgml
 1) for 24h and the expression of cyclin D1, E, A,
cdk4, cdk2, p21 and p27 in cell extracts was evaluated by western
blot analysis with respective antibody. Neither of the G1 regulatory
proteins cyclin-D1, cdk4 or p21, G1-late phase or G1/S-phase
regulatory proteins cyclin E, A and cdk2 demonstrated changes in
their expression after the treatment with PL (Figure 3A). Never-
theless, PL (0.5 and 1.0mgml
 1) markedly induced expression of a
cyclin-dependent kinase inhibitor p27 (Figure 3B). Therefore, PL
inhibits proliferation of breast cancer cells by the upregulation of
p27 resulting in S-phase cell cycle arrest.
Phellinus linteus suppresses invasive behaviour of breast
cancer cells
The ability of cancers to metastasise is directly associated to cell
adhesion, migration and invasion. Integrin receptor aVb3 is
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Figure 2 Effect of PL on colony formation of MDA-MB-231 cells.
Anchorage-independent growth (colony formation) of MDA-MB-231 cells
was assessed on 1% agarose after incubation for 14 days with culture media
containing: (A) 0mgml
 1 PL, (B) 0.25mgml
 1 PL, (C) 0.5mgml
 1 PL,
(D) 1.0mgml
 1 as described in Materials and Methods. (E) The number of
colonies was determined as described in Materials and Methods. The data
are the means±s.d. from three experiments. *Po0.05.
Table 1 Effect of PL on cell cycle distribution
Time (h)
PL
(mg per ml) G0/G1 S G2/M subG0/G1
00 4 8 ±0.6 26±0.4 26±0.4 0.5±0.04
24 0 52±0.5 30±0.7 17±0.2 2.3±0.10
48 0 51±1.1 30±0.3 19±0.9 0.7±0.09
0 0.5 47±2.7 27±1.2 26±1.9 1.2±0.36
24 0.5 47±1.3 34±1.1* 18±0.2 0.9±0.37
48 0.5 39±1.7 44±1.7* 17±0.9 1.1±0.20
Cell cycle distribution G0/G1, S, G2/M and subG0/G1 in %. *Statistical significance
Po0.005 for cells at S phase (24 and 48h) vs control (0h) from three experiments.
0 0.06 0.13 0.25 0.5 1.0
0.13 0.25 0.5 1.0
 PL (mg per ml) 
Cyclin D1
-Actin
-Actin
Cdk4
0 PL (mg per ml) 
-Actin
Cyclin E
Cyclin A
Cdk2
p21
PL (mg per ml) 
p27
-Actin
24 h 72 h 48 h
1.0 1.2 1.3 1.1 0.7 1.4 1.2 1.5 2.3
1.0 1.0 0.5 0.5 0 0 1.0 0.5 0
Ratio p27/-actin
Figure 3 Effect of PL on the expression of cell cycle regulatory proteins.
MDA-MB-231 cells were treated with PL (0–1.0mgml
 1) for (A)2 4h ,o r
(B) 24–48h and whole-cell extracts were subjected to Western blot
analysis. The expression of cyclin D1, cyclin E, cyclin A, cdk2, cdk4, p21 and
p27 was evaluated by western blot analysis with their respective antibodies.
The equal protein loading was verified with anti-b-actin antibody. The
results are representative of three separate experiments. The expression
level of p27 (ratio p27/b-actin) was quantified by densitometry as
described in Materials and Methods.
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with extracellular matrix (ECM) protein vitronectin (Wong et al,
1998). To investigate if PL affects adhesion of invasive breast
cancer cells, MDA-MB-231 cells were pretreated with PL
(0–0.5mgml
 1) for 24h and their adhesion to vitronectin was
determined. As seen in Figure 4A, adhesion of MDA-MB-231 cells
was markedly suppressed by the PL treatment. Next, we evaluated
if PL also inhibits cell migration. MDA-MB-231 cells were
pretreated with PL (0–1.0mgml
 1) for 1h and cell migration
was determined after additional 5h of incubation. As seen in
Figure 4B, PL also markedly suppressed migration of breast cancer
cells in a dose-dependent manner. Finally, the effect of PL on cell
invasiveness was evaluated. MDA-MB-231 cells were plated on the
Matrigel-coated filters in the presence of PL (0–1.0mgml
 1) and
the amount of cells invaded through Matrigel counted after 48h of
incubation. As seen in Figure 4C, PL inhibits invasion of
MDA-MB-231 cells in a dose–response manner. Because cancer
metastasis and invasiveness are associated with the uPA–uPA
receptor (uPAR) system, we evaluated whether PL affects secretion
of uPA from cancer cells. MDA-MB-231 cells were treated with
PL (0–1.0mgml
 1) for 24h and uPA secretion evaluated by
western blot analysis in conditioned media. In agreement with the
data demonstrating inhibition of cell adhesion, migration and
invasion PL markedly decreased secretion of uPA from MDA-MB-
231 cells (Figure 4D).
Phellinus linteus inhibits capillary morphogenesis of
endothelial cells through the suppression of VEGF
secretion
Capillary morphogenesis (tube formation) of human endothelial
cells is one of the first important steps in angiogenesis associated
with the cancer progression and metastasis. Because cancer
microenvironment contains a variety of cells, we also evaluated
if the inhibition of capillary morphogenesis of endothelial cells can
be mediated through breast cancer cells. Therefore, we determined
if PL itself or conditioned media from breast cancer cells exposed
to PL suppress capillary morphogenesis of HAECs. Human aortic
endothelial cells grown on Matrigel were treated directly with PL
(0–0.5mgml
 1) or with the conditioned media from MDA-MB-231
cells treated with PL (0–0.5mgml
 1, PL-CM) for 24h, and tube
formation were evaluated. As seen in Figure 5A, PL significantly
suppressed capillary morphogenesis of HAECs. Moreover, condi-
tioned media from MDA-MB-231 cells without PL induced
capillary morphogenesis of HAECs (PL vs PL-CM at 0 PL), and
conditioned media from cells exposed to PL (PL-CM) also
suppressed capillary morphogenesis of HAECs in a dose–response
manner (Figure 5A–C). Because MDA-MB-231 cells express pro-
angiogenic VEGF (Basu et al, 2005), we hypothesised that secreted
VEGF from these cells induces capillary morphogenesis of
endothelial cells, which can be inhibited by PL. Therefore, we
evaluated whether PL inhibits secretion of VEGF from MDA-MB-
231 cells treated with PL (0–0.5mgml
 1). As seen in Figure 5D,
secretion of VEGF from MDA-MB-231 cells was markedly
decreased by PL in a dose–response manner. Collectively, our
data suggest that PL inhibits capillary morphogenesis of endothe-
lial cells directly as well as indirectly through the suppression of
secretion of VEGF from breast cancer cells.
Phellinus linteus inhibits activity of AKT kinase
AKT serine-threonine kinase (protein kinase B) regulates a variety
of cellular processes through the phosphorylation of a wide
spectrum of downstream substrates finally resulting in the
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Figure 4 Effect of PL on invasive behaviour of MDA-MB-231 cells. (A) Cell adhesion. MDA-MB-231 cells were treated with PL (0–0.5mgml
 1) for 24h
and cell adhesion to vitronectin determined as described in Materials and Methods. Each bar represents the mean±s.d. of three experiments. *Po0.05.
(B) Cell migration. Cell was determined after 5h of incubation in the presence of PL (0–1.0mgml
 1) in Boyden Chambers as described in Materials and
Methods. Each bar represents the mean±s.d. of three experiments. *Po0.05. (C) Cell invasion. Cell invasion was determined after 24h of incubation in the
presence of PL (0–1.0mgml
 1) in Boyden Chambers coated with Matrigel as described in Materials and Methods. Each bar represents the mean±s.d. of
three experiments. *Po0.05. (D) uPA secretion. MDA-MB-231 cells were treated with PL (0–1.0mgml
 1) for 24h, and the expression of uPA detected in
conditioned media with anti-uPA antibody by western blot analysis as described in Materials and Methods. The secretion of uPA was quantified by
densitometry as described in Materials and Methods. The results are representative of three separate experiments.
Inhibition of AKT signalling by Phellinus mushroom
D Sliva et al
1352
British Journal of Cancer (2008) 98(8), 1348–1356 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sexpression of proteins involved in cell proliferation, invasiveness
and angiogenesis among others (Woodgett, 2005; Dillon et al,
2007). To determine if PL modulates AKT activity in breast cancer
cells, MDA-MB-231 cells were treated with PL (0–1.0mgml
 1) for
24h and the phosphorylation status of AKT evaluated in whole-cell
extracts by western blot analysis. As seen in Figure 6A, PL inhibits
phosphorylation of AKT at Thr
308 in a dose–response manner. In
addition, PL treatment also markedly decreased phosphorylation
of AKT at Ser
473 (Figure 6B).
To evaluate if the suppression of AKT activity PL is directly
responsible for the inhibition of capillary morphogenesis through
the downregulation of expression of VEGF in MDA-MB-231 cells,
we used a pharmacological approach with specific AKT inhibitors.
Therefore, MDA-MB-231 cells were treated with LY294002 (10mM)
or AKT inhibitor III (10mM) for 24h, and secretion of VEGF was
evaluated. As seen in Figure 7A, AKT inhibitors markedly
BC
V
E
G
F
 
(
p
g
 
p
e
r
 
m
l
)
0
2000
4000
6000
8000
10000
0 0.125 0.25
PL (mg per ml)
∗
∗
0 0.125 0.25 0.5
PL (mg per ml)
0
20
40
60
80
100
∗
∗ #
#
#
P<0.05
P<0.05
P<0.05
A
D
C
a
p
i
l
l
a
r
y
 
m
o
r
p
h
o
g
e
n
e
s
i
s
 
(
n
o
d
e
s
 
p
e
r
 
f
i
e
l
d
)
P<0.05
0.5
PL
PL-CM
Figure 5 Phellinus linteus inhibits capillary morphogenesis of aortic
endothelial cells. (A) HAECs were seeded onto Matrigel, and the cells
were treated with PL (0–0.5mgml
 1) (black bars) or with the conditioned
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Figure 6 Effect of PL on AKT activity. MDA-MB-231 cells were treated
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 1) for 24h and whole-cell extracts were subjected
to western blot analysis with (A) anti-p-AKT-Thr
308 or (B) anti-p-AKT-
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antibody. The level of pAKT (ratio pAKT/AKT) was quantified by
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Figure 7 AKT inhibition suppresses VEGF secretion and capillary
morphogenesis. MDA-MB-231 cells were treated with vehicle, LY294002
(10mM) or AKT inhibitor III (10mM) for 24h and conditioned media
collected. (A) Vascular endothelial growth factor secretion from MDA-MB-
231 cells and (B) capillary morphogenesis of HEAC was determined as
described in Materials and Methods. Each bar represents the mean±s.d. of
minimum three experiments repeated twice. *Po0.05.
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Moreover, conditioned media from MDA-MB-231 cells treated
with LY294002 and AKT inhibitor III also inhibited capillary
morphogenesis of endothelial cells (Figure 7B). Therefore, these
data suggest that the inhibition of angiogenesis in vitro by PL is
mediated, to some extent, through the suppression of AKT activity,
which results in the suppression of secretion of VEGF from breast
cancer cells.
DISCUSSION
Regardless of different theories of biology of breast cancer as (i) a
local disease that spreads over time to develop distant metastases;
(ii) a systemic disease from the outset, with distant metastases
present well before diagnosis (iii) or the combination of both as a
heterogeneous disease, cancer metastasis is one of the major
medical problems in breast cancer patients (Punglia et al, 2007).
While several chemotherapeutic agents or their combinations (e.g.
taxanes, trastumazab, gemcitabine or capecitabine) demonstrated
activity in the metastatic breast cancer setting (Tripathy, 2007),
there is a paucity of natural antiproliferative and anti-metastatic
nontoxic agents.
As demonstrated practically four decades ago, polysaccharide
extracts from basidiomycete fungus PL suppressed tumour growth
in vivo (Chihara et al, 1969). In addition, PL also reduced tumour
growth and the frequency of pulmonary metastasis without toxic
effects (Han et al, 1999). Recent studies elucidated some of the
molecular mechanism(s) responsible for the inhibition of growth
through cell cycle arrest and induction of apoptosis in lung and
prostate cancer cells (Collins et al, 2006; Guo et al, 2007; Zhu et al,
2007). Nevertheless, the molecular mechanism(s) responsible for
the inhibition of invasive behaviour and angiogenesis was not fully
addressed.
In the present study, we demonstrate that PL inhibits cell
proliferation (anchorage-dependent growth) as well as colony
formation (anchorage-independent growth) of highly invasive
breast cancer cells through the S-phase cell cycle arrest mediated
by the upregulation of expression of p27. Cell growth, which is the
reflection of the progression of cell cycle, is aberrantly regulated in
the majority of cancers. The cell cycle is regulated by a series of
checkpoints employing cyclins, cdks and cdk inhibitors (Sherr,
1966). p27 is one of the cdk inhibitors, which binds to S-phase
cyclin–cdk complexes and inhibits their cell cycle stimulatory
activities. Because a loss of p27 expression has been linked to the
aggressive behaviour in a variety of human epithelial tumours
including breast cancer, the induction of p27 expression could lead
to cell cycle arrest and inhibition of tumour growth (Tan et al,
1997; Lloyd et al, 1999; Macri and Loda, 1999). Our data are in
agreement with recent papers also demonstrating the inhibition of
growth of prostate cancer and leukaemia cells through the S-phase
cell cycle arrest by the upregulation of expression of p27 (Zhang
et al, 2006; Shishodia et al, 2007). Recently, Guo et al (2007)
demonstrated that PL suppresses growth of lung cancer cells
through G1-phase cell cycle arrest mediated by the inhibition of
cdk2, 4 and 6 activities. Our results show cell cycle arrest at S phase
in breast cancer cells through the upregulation of p27. Never-
theless, our data are not in a disagreement with Guo et al because
the passage through G1 phase into S phase is regulated by the
activities of cdk2, 4 and 6, which are controlled by cdk inhibitor
p27 (Slingerlan and Pagano, 2000). Moreover, cell cycle arrest at S
phase can also be interpreted as the arrest at G1-S, because the
majority of cells are at G0/G1 and S but not G2 phases (Table 1).
Most importantly, PL suppresses growth of cancer cells by the cell
cycle arrest.
Here, we show that PL inhibits adhesion, migration and invasion
through the suppression of secretion of uPA from highly invasive
breast cancer cells. Our data are in agreement with the study by
Lee et al (2005) demonstrating the inhibition of adhesion, invasion
and expression of uPA in mouse melanoma cells. Furthermore,
our data suggest the mechanism of inhibition of invasiveness
by PL. Therefore, secreted uPA from breast cancer cells interacts
with uPAR and converts plasminogen to plasmin (Blasi and
Carmeliet, 2002). Plasmin degrades ECM components and
stimulates other proteolytic enzymes (MMPs), which through the
degradation of ECM contribute to cell invasion (Blasi and
Carmeliet, 2002). Secreted uPA can bind to uPAR and forms a
complex with integrin receptor aVb3, which through its interaction
with vitronectin is involved in adhesion and migration of breast
cancer cells (Slivova et al, 2005). Inhibition of uPA secretion will
reduce the formation of uPA–uPAR–aVb3–vitronectin complex,
with the consequent suppression of adhesion and migration of
invasive breast cancer cells. Alternatively, PL can also modulate
activities of other proteins involved in the invasive behaviour of
breast cancer cells (e.g. matrix metalloproteinases, b1 and b4
integrins, epidermal growth factor receptors and others (Carraway
and Sweeney, 2006; Bissell, 2007)). Nevertheless, in the present
study, we propose that PL suppresses invasiveness through the
inhibition of uPA secretion. Finally, we and others have previously
demonstrated that inhibition of uPA suppressed invasiveness
of breast cancer cells (Sliva et al, 2002b; Das et al, 2003: Mi et al,
2006).
Recently, Song et al (2003) demonstrated anti-angiogenic
activity of PL in chorioallantoic membrane (CAM) chick embryo
assay. However, the mechanism of the inhibition of angiogenesis
by PL, related to cancer, was not previously addressed. In the
present study, we demonstrate that PL inhibits one of the first
steps in angiogenesis – tube formation of endothelial cells. While
PL directly suppressed capillary morphogenesis of endothelial
cells, our data further suggest that this effect can be mediated by
the inhibition of secretion of VEGF from breast cancer cells.
Although in our experimental conditions it was impossible to
remove PL from the conditioned media from breast cancer cells
(PL-CM), and therefore their inhibitory effect on capillary
morphogenesis of HEACs could be considered as a direct effect
of PL on HEACs, our data suggest that both (direct and indirect)
effects are involved. Thus, (i) conditioned media from breast
cancer cells without PL significantly increased capillary morpho-
genesis of endothelial cells, suggesting that proangiogenic factor is
released from breast cancer cells, (ii) PL itself as well as
conditioned media containing PL suppressed capillary morpho-
genesis and (iii) the secretion of VEGF from breast cancer cells was
inhibited by PL. In agreement with our observation, suppression of
endothelial capillary morphogenesis through the inhibition of
secreted VEGF from a variety of cancer cells was described recently
(Fukumoto et al, 2005; Stanley et al, 2005; Jang et al, 2007; Kong
et al, 2007). Therefore, inhibition of specific pro-angiogenic
protein within cancer cells will affect the whole cancer micro-
environment (containing different cells) and will finally result in
the suppression of tumour angiogenesis.
One of the suitable molecular cancer targets is AKT kinase,
which inhibition in breast cancer cells resulted in cell cycle arrest,
inhibition of growth and colony formation, inhibition of migra-
tion, invasion and suppression of angiogenesis (Das et al, 2003;
Yacoub et al, 2003; Jiang et al, 2004a; Basu et al, 2005; Fukumoto
et al, 2005; Jallal et al, 2007). Our data clearly demonstrate that PL
suppresses AKT activity through the inhibition of AKT phosphory-
lation at Thr
308 and at Ser
473 in MDA-MB-231 cells, which
demonstrate high levels of constitutively active AKT. Furthermore,
inhibition of AKT with LY294002 and more specific AKT inhibitor
III suppressed secretion of VEGF from breast cancer cells resulting
in the decrease of capillary morphogenesis of endothelial cells. Our
observation is in agreement with Xia et al (2006) who demon-
strated, by using siRNA against AKT, the downregulation of VEGF
expression in ovarian cancer cells, and the inhibition of
angiogenesis in CAM chick embryo assay.
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sIn conclusion, our study suggests PL as a natural compound
possessing antiproliferative, antimetastatic and anti-angiogenic
effects, which could be considered for the therapy of invasive
breast cancers. However, further studies are necessary to confirm
and evaluate these anticancer effects in vivo.
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